A detailed history of Sargent Bickham Lagudis LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 1,530 shares of NVO stock, worth $162,378. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,530
Previous 1,530 -0.0%
Holding current value
$162,378
Previous $152,000 36.18%
% of portfolio
0.02%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 27, 2022

SELL
$95.28 - $116.93 $2,096 - $2,572
-22 Reduced 1.42%
1,530 $152,000
Q2 2022

Jul 13, 2022

BUY
$103.24 - $121.81 $12,698 - $14,982
123 Added 8.61%
1,552 $173,000
Q3 2021

Nov 05, 2021

SELL
$84.42 - $106.62 $28,787 - $36,357
-341 Reduced 19.27%
1,429 $137,000
Q2 2021

Jul 19, 2021

SELL
$67.66 - $84.76 $4,736 - $5,933
-70 Reduced 3.8%
1,770 $148,000
Q1 2021

May 24, 2021

BUY
$67.06 - $75.82 $5,633 - $6,368
84 Added 4.78%
1,840 $124,000
Q4 2020

May 24, 2021

SELL
$63.89 - $73.8 $5,366 - $6,199
-84 Reduced 4.57%
1,756 $123,000
Q4 2020

May 24, 2021

BUY
$63.89 - $73.8 $58,459 - $67,527
915 Added 98.92%
1,840 $124,000
Q3 2019

Sep 14, 2021

SELL
$47.54 - $53.43 $49,298 - $55,406
-1,037 Reduced 52.85%
925 $48,000
Q2 2019

Sep 13, 2021

SELL
$46.79 - $52.47 $9,358 - $10,494
-200 Reduced 9.25%
1,962 $100,000
Q1 2019

Sep 13, 2021

SELL
$46.36 - $52.63 $13,444 - $15,262
-290 Reduced 11.83%
2,162 $113,000
Q1 2017

Sep 13, 2021

SELL
N/A
-2,321 Reduced 48.63%
2,452 $84,000
Q4 2016

Sep 13, 2021

BUY
N/A
4,391 Added 1149.48%
4,773 $171,000
Q3 2016

Sep 13, 2021

SELL
N/A
-65,675 Reduced 99.42%
382 $2.41 Million
Q2 2016

Sep 07, 2021

BUY
N/A
3,020 Added 4.79%
66,057 $3.55 Million
Q1 2016

Sep 07, 2021

BUY
N/A
63,037
63,037 $3.42 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $240B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Sargent Bickham Lagudis LLC Portfolio

Follow Sargent Bickham Lagudis LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Bickham Lagudis LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Bickham Lagudis LLC with notifications on news.